Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 18 Saturday Friday Sunday Monday Tuesday Publication Only PUBLICATION ONLY Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors ASCO Selection Status Session Name e14587 Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Falchook G Falchook G, McKean M, Kelly W, Patel M, Bupathi M, Garmezy B Publication Only Developmental Therapeutics— Immunotherapy e15014 A novel oral microtubule inhibitor utidelone capsule (UTD2): A phase 1 clinical study to assess the tolerability, safety, and efficacy in advanced solid tumors. Wang J Wang J, Patel M Publication Only Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology e13748 A comprehensive analysis of patient demographics and disparities in contemporary oncology clinical trials (2022-2023). Reddy N Subbiah I, Subbiah V Publication Only Care Delivery/Models of Care e23213 Targeted interventions to address local challenges in HR+/HER2- and HER2+ breast cancer treatment in community-based settings. Mahtani R Hamilton E Publication Only Quality Care/Health Services Research e14581 Intravenous infusion (IV) or intracavitary perfusion (IP) of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody: Analyses of two phase 1 studies. Niu J McKean M Publication Only Developmental Therapeutics— Immunotherapy e14681 ADPORT-601: First-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in patients with select advanced solid tumors. Fong L Tester W, Falchook G Publication Only Developmental Therapeutics— Immunotherapy e13601 Treatment patterns among HCPs and concordance with expert recommendations in HER2-negative early breast cancer: Analysis of an interactive online treatment decision support tool. Brandt K Yardley D Publication Only Care Delivery/Models of Care e13679 Improving ethnic and racial diversity within clinical trial populations through community recruitment and inclusion initiatives: Experience from MyTACTIC. Zuniga R Spigel D Publication Only Care Delivery/Models of Care e21018 The impact of an inclusion council in an independent community oncology practice. Fleming M Fleming M Publication Only Medical Education and Professional Development e19036 Real-world cost of disease progression (PD) after frontline (1L) R-CHOP in diffuse large B-cell lymphoma (DLBCL): An analysis of a large US claims database. Burke J Burke J Publication Only Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia